COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO

Reuters2021-07-07

July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).

Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.

About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.

Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.

The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.

Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol "STVN".

Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

BlueDragon
2021-07-08
BlueDragon
Ok
Sharoncpg
2021-07-08
Sharoncpg
Ok
Sharoncpg
2021-07-08
Sharoncpg
Ok
mizseah
2021-07-08
mizseah
Well done its good news
Moon168
2021-07-08
Moon168
[Cry] [Cry]
carrotman
2021-07-08
carrotman
Can they still make it? Considering a few vaccines are already in the market.
- Rteo:
  Late To Market

Leave a comment

105

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128740137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-07 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128740137","market":"us","top_or_hot":-1,"title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","media":"Reuters","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":".IXIC","symbol_name":"NASDAQ Composite","start_time":0,"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","article_id":"1128740137","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","pubTimestamp":1625668639,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","collect":0,"end_time":0,"defaultTopTitle":"reuters.com","property":[],"viewcount":null,"language":"en","relate_stocks":{".IXIC":"NASDAQ Composite"},"translate_title":"新冠肺炎疫苗瓶制造商Stevanato在美国首次公开募股估值为7英镑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":0.9},"content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":149112955,"gmtCreate":1625708988277,"gmtModify":1703746821149,"author":{"id":"4087932884013320","authorId":"4087932884013320","name":"BlueDragon","avatar":"https://static.tigerbbs.com/431c326e19a16844e147d10866565f27","vip":1,"crmLevel":11,"crmLevelSwitch":1,"idStr":"4087932884013320","authorIdStr":"4087932884013320"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149112955","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","kind":"news","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=en_US&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1,"symbols_score_info":{".IXIC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149911725,"gmtCreate":1625700879467,"gmtModify":1703746532725,"author":{"id":"3577610300187690","authorId":"3577610300187690","name":"Sharoncpg","avatar":"https://static.tigerbbs.com/9c1567648b16c497608badcc662d4756","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3577610300187690","authorIdStr":"3577610300187690"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149911725","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","kind":"news","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=en_US&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1,"symbols_score_info":{".IXIC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149913930,"gmtCreate":1625700805420,"gmtModify":1703746529929,"author":{"id":"3577610300187690","authorId":"3577610300187690","name":"Sharoncpg","avatar":"https://static.tigerbbs.com/9c1567648b16c497608badcc662d4756","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3577610300187690","authorIdStr":"3577610300187690"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149913930","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","kind":"news","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=en_US&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1,"symbols_score_info":{".IXIC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149994465,"gmtCreate":1625700288057,"gmtModify":1703746510834,"author":{"id":"3573873419404517","authorId":"3573873419404517","name":"mizseah","avatar":"https://static.tigerbbs.com/ac4cc904a19ed963f6dceca76fd16300","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3573873419404517","authorIdStr":"3573873419404517"},"htmlText":"Well done its good&nbsp;news","listText":"Well done its good&nbsp;news","text":"Well done its good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149994465","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","kind":"news","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=en_US&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1,"symbols_score_info":{".IXIC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149905829,"gmtCreate":1625699654461,"gmtModify":1703746496129,"author":{"id":"4088063093928140","authorId":"4088063093928140","name":"Moon168","avatar":"https://static.tigerbbs.com/33a1d014ad313b464a79e0ff58f37331","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4088063093928140","authorIdStr":"4088063093928140"},"htmlText":"[Cry]&nbsp;[Cry]&nbsp;","listText":"[Cry]&nbsp;[Cry]&nbsp;","text":"[Cry] [Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149905829","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","kind":"news","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=en_US&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1,"symbols_score_info":{".IXIC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149072515,"gmtCreate":1625699016037,"gmtModify":1703746479787,"author":{"id":"3564197930660816","authorId":"3564197930660816","name":"carrotman","avatar":"https://static.tigerbbs.com/9b29e1032c7343cf14e78c210f93267f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3564197930660816","authorIdStr":"3564197930660816"},"htmlText":"Can they still make it? Considering a few vaccines are already in the market.","listText":"Can they still make it? Considering a few vaccines are already in the market.","text":"Can they still make it? Considering a few vaccines are already in the market.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/149072515","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","kind":"news","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=en_US&edition=fundamental","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1,"symbols_score_info":{".IXIC":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5153982,"gmtCreate":1625700976901,"gmtModify":1663230671946,"authorId":3582595806100338,"author":{"id":3582595806100338,"idStr":"3582595806100338","authorId":3582595806100338,"name":"Rteo","avatar":"https://static.tigerbbs.com/ba4c61a94c707cd25f18400b8cc52a4c","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.22","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149072515,"type":1,"supId":0,"prevId":0,"content":"Late To Market","text":"Late To Market","html":"Late To Market"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":105,"commentSize":19,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128740137","isCrawlerRequest":true}